Carlos A. Ramos

10.4k total citations · 5 hit papers
107 papers, 6.2k citations indexed

About

Carlos A. Ramos is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Carlos A. Ramos has authored 107 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 40 papers in Immunology and 29 papers in Molecular Biology. Recurrent topics in Carlos A. Ramos's work include CAR-T cell therapy research (61 papers), Immune Cell Function and Interaction (22 papers) and Virus-based gene therapy research (18 papers). Carlos A. Ramos is often cited by papers focused on CAR-T cell therapy research (61 papers), Immune Cell Function and Interaction (22 papers) and Virus-based gene therapy research (18 papers). Carlos A. Ramos collaborates with scholars based in United States, Portugal and Germany. Carlos A. Ramos's co-authors include Gianpietro Dotti, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Barbara Savoldo, Adrian P. Gee, Hao Liu, Enli Liu, Catherine M. Bollard and Bambi Grilley and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Carlos A. Ramos

103 papers receiving 6.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

2011 794 citations Barbara Savoldo, Carlos A. Ramos et al. Journal of Clinical Investigation profile →
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

2014 569 citations Carlos A. Ramos, Enli Liu et al. Blood profile →
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

2013 384 citations Catherine M. Bollard, Vicky Torrano et al. profile →
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

2020 340 citations Carlos A. Ramos et al. profile →
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion

2022 204 citations Carlos A. Ramos et al. profile →

Peers

Countries citing papers authored by Carlos A. Ramos

Since Specialization

Citations

This map shows the geographic impact of Carlos A. Ramos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos A. Ramos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos A. Ramos more than expected).

Fields of papers citing papers by Carlos A. Ramos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos A. Ramos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos A. Ramos. The network helps show where Carlos A. Ramos may publish in the future.

Co-authorship network of co-authors of Carlos A. Ramos

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos A. Ramos. A scholar is included among the top collaborators of Carlos A. Ramos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos A. Ramos. Carlos A. Ramos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant 2024 ·Transplantation and Cellular Therapy ·Ibrahim N. Muhsen, (unknown), Tao Wang, Meng-Fen Wu, Premal Lulla, Carlos A. Ramos, Rammurti T. Kamble, Helen E. Heslop, George Carrum, LaQuisa Hill	2
2	Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors 2024 ·Cytotherapy ·(unknown), (unknown), Tao Wang, Meng‐Fen Wu, (unknown), Thomas Pfeiffer, Shoba A. Navai, Andras Heczey, Meenakshi Hegde, Nabil Ahmed, Sarah Burkhead Whittle, LaQuisa Hill, Caridad Martinez, Robert A. Krance, Carlos A. Ramos, Rayne H. Rouce, Premal Lulla, Helen E. Heslop, Bilal Omer, (unknown)	0
3	Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas 2023 ·Hematology/Oncology Clinics of North America ·Ibrahim N. Muhsen, LaQuisa Hill, Carlos A. Ramos	3
4	T cell immune profiling of respiratory syncytial virus for the development of a targeted immunotherapy 2023 ·British Journal of Haematology ·(unknown), (unknown), Manik Kuvalekar, Ayumi Watanabe, (unknown), Carlos A. Ramos, Ann M. Leen, Spyridoula Vasileiou	6
5	Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy 2023 ·Cytotherapy ·(unknown), (unknown), Sachin G. Thakkar, Meng-Fen Wu, (unknown), Tao Wang, Bambi Grilley, Helen E. Heslop, Carlos A. Ramos, Margaret A. Goodell, Premal Lulla	5
6	OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL) 2023 ·Hematological Oncology ·Carlos A. Ramos, David H. Quach, Premal Lulla, Rayne H. Rouce, Sandhya Sharma, (unknown), Nazila Nouraee, (unknown), (unknown), Sachin G. Thakkar, Birju Mehta, (unknown), Emily M. Hsieh, Huimin Zhang, Bambi Grilley, Natalia Lapteva, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney	8
7	Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting 2023 ·Clinical Cancer Research ·Thomas Pfeiffer, Ifigeneia Tzannou, Meng-Fen Wu, Carlos A. Ramos, Ghadir Sasa, Caridad Martinez, Premal Lulla, Robert A. Krance, (unknown), (unknown), Swati Naik, Claire Bocchini, (unknown), (unknown), (unknown), Tao Wang, Helen E. Heslop, Ann M. Leen, Bilal Omer	49
8	Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas 2023 ·Blood ·LaQuisa Hill, Rayne H. Rouce, Meng-Fen Wu, Tao Wang, Royce Ma, Huimin Zhang, Birju Mehta, Natalia Lapteva, Zhuyong Mei, Tyler S. Smith, Lina Yang, Madhuwanti Srinivasan, (unknown), Carlos A. Ramos, Premal Lulla, (unknown), Bambi Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin	30
9	Combined autologous CD30.CAR‐T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study) 2023 ·Hematological Oncology ·Sairah Ahmed, Matthew Mei, David M. Kurtz, Amer Beitinjaneh, (unknown), Carlos A. Ramos, Jacob J. Chabon, André Schultz, (unknown), (unknown), Ash A. Alizadeh, Ivan D. Horak, Helen E. Heslop	0
10	Allogeneic NKT Cells Expressing a CD19-Specific CAR in Patients with Relapsed or Refractory B-Cell Malignancies 2022 ·Transplantation and Cellular Therapy ·Carlos A. Ramos, Amy N. Courtney, Simon N. Robinson, Olga Dakhova, Premal Lulla, Rammurti T. Kamble, George Carrum, Tao Wang, Chunchao Zhang, Erica J. Di Pierro, (unknown)	4
11	Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma 2022 ·Bone Marrow Transplantation ·Brian D. Friend, Ibrahim N. Muhsen, Shreeya Patel, LaQuisa Hill, Premal Lulla, Carlos A. Ramos, Sai Ravi Pingali, Rammurti T. Kamble, (unknown), (unknown), (unknown), Erin Doherty, John Craddock, Ghadir Sasa, Meng-Fen Wu, Tao Wang, Caridad Martinez, Robert A. Krance, Helen E. Heslop, George Carrum	1
12	Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma 2020 ·Nature Communications ·Tseng Hsiang-Chi, Wei Xiong, Saiaditya Badeti, Yan Yang, (unknown), Ting Liu, Carlos A. Ramos, Gianpietro Dotti, Luke Fritzky, (unknown), Qing Yi, James V. Guarrera, Wei‐Xing Zong, Chen Liu, Dongfang Liu	140
13	Safety and Efficacy of Adoptively Transferred Donor-Derived Tumor-Directed T Cells with Relapsed AML Post-Allogeneic HSCT 2017 ·Blood ·Premal Lulla, Swati Naik, Ifigeneia Tzannou, Carlos A. Ramos, Rammurti T. Kamble, Catherine Robertson, Ayumi Watanabe, Manik Kuvalekar, Bambi Grilley, George Carrum, Helen E. Heslop, Juan F. Vera, Ann M. Leen	1
14	Clinical responses with T lymphocytes targeting malignancy-associated κ light chains 2016 ·Journal of Clinical Investigation ·Carlos A. Ramos, Barbara Savoldo, Vicky Torrano, Brandon Ballard, Huimin Zhang, Olga Dakhova, Enli Liu, George Carrum, Rammurti T. Kamble, Adrian P. Gee, Zhuyong Mei, Meng-Fen Wu, Hao Liu, Bambi Grilley, Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop, Gianpietro Dotti	234
15	Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity 2014 ·Clinical Cancer Research ·Alana A. Kennedy‐Nasser, Stephanie Ku, (unknown), Yasmin Hazrat, Meng-Fen Wu, Hao Liu, Jos Melenhorst, A. John Barrett, Sawa Ito, Aaron E. Foster, Barbara Savoldo, Eric Yvon, George Carrum, Carlos A. Ramos, Robert A. Krance, Kathryn Leung, Helen E. Heslop, Malcolm K. Brenner, Catherine M. Bollard	145
16	Acute gout at engraftment following hematopoietic transplantation 2011 ·American Journal of Hematology ·Rammurti T. Kamble, (unknown), Carlos A. Ramos, George Carrum	1
17	Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization 2006 ·Journal of Clinical Investigation ·Hans‐Georg Kopp, Andrea T. Hooper, M. Johan Broekman, Scott T. Avecilla, Isabelle Petit, Min Luo, Till Milde, Carlos A. Ramos, Fan Zhang, (unknown), Paul Börnstein, David Jin, Aaron J. Marcus, Shahin Rafii	80
18	Human mesenchymal stem cells are tolerized by mice and improve skin and spinal cord injuries 2005 ·Transplantation Proceedings ·Eduardo Mansilla, Gustavo H. Marín, F. Sturla, (unknown), M.A Gil, Eduardo Salas, (unknown), Giorgio Piccinelli, Silvia Bossi, Lucía Petrelli, (unknown), Carlos A. Ramos, Carlos Soratti	95
19	Molecular Signatures of Proliferation and Quiescence in Hematopoietic Stem Cells 2004 ·PLoS Biology ·(unknown), Akil Merchant, Carlos A. Ramos, (unknown), Andrew Young, Chad A. Shaw, Margaret A. Goodell	266
20	The dynamics of coiled bodies in the nucleus of adenovirus-infected cells. 1996 ·Molecular Biology of the Cell ·Luciana Magalhães Rebêlo Alencar, (unknown), Carlos A. Ramos, Kerstin Bohmann, Angus I. Lamond, Maria Carmo‐Fonseca	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact